Skip to main content
TipRanks
Go Ultimate75% OFF

OssDsign AB (OSSD) AI Stock Analysis

1 Followers
SE:OSSD

OssDsign AB

(Nasdaq OMX AB:OSSD)

Select Model
Rating:46Neutral
Price Target:SEK 3.50â–²(5.11% Upside)
Action:reiterated
Date:11/05/26

The score is held back primarily by weak financial performance: despite outstanding gross margins and a debt-free balance sheet, OssDsign is still loss-making with roughly SEK 60 million of annual cash burn and a recent TTM revenue decline of about 5%. Valuation offers little support given negative earnings and no dividend. Technicals are mixed — the price has recovered above its 20- and 50-day averages, but remains well below the 100- and 200-day averages, reflecting a longer-term downtrend. The strong equity cushion and clear trend of narrowing losses are the main positives that prevent a lower score.

Positive Factors
High Gross MarginsGross margins in the mid-70% to mid-90% range indicate attractive unit economics and leave meaningful room to support commercial investment as revenue scales. Although profitability is still negative, this margin profile can provide operating leverage if growth resumes and costs are controlled.
Negative Factors
Persistent Operating LossesEBIT and net income remain deeply negative across all reported periods, so the attractive gross margin has not yet translated into profitability. Continued losses weaken returns on shareholder capital and indicate that the business remains materially distant from break-even.

OssDsign AB (OSSD) vs. iShares MSCI Sweden ETF (EWD)

-80%-60%-40%-20%0%20%40%SE:OSSD-68.82%EWD+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 368.38M
Dividend Yield
―
Average Volume (3M)
217.22K
Price to Earnings (P/E)
-7.4
Beta (1Y)
-0.63
Revenue Growth
-11.89%
EPS Growth
-11.85%
Country
Sweden
Employees
38
Sector
General
Sector Strength
55
Industry
Medical - Devices

OssDsign AB Business Overview & Revenue Model

Company Description

OssDsign AB (publ) specializes in the innovation, manufacturing, and distribution of advanced implant and material technologies crucial for bone regeneration. The company operates across a broad international market, including Sweden, Germany, the Un...

OssDsign AB Financial Statement Overview

Summary

OssDsign combines exceptional gross margins of 93–96% and a nearly debt-free balance sheet (SEK 283 million equity, SEK 0.7 million debt) with persistent unprofitability. TTM revenue of SEK 155.5 million produced a SEK 50.9 million net loss (-33% net margin), and free cash flow was negative SEK 61.6 million. Losses and cash burn have narrowed meaningfully since 2023, but a roughly 5% TTM revenue decline raises questions about growth durability, and continued burn erodes equity and could eventually require dilutive fundraising.

Income Statement

38Negative

Balance Sheet

77Positive

Cash Flow

27Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue155.51M180.16M133.94M112.16M56.98M31.73M
Gross Profit145.34M173.47M127.75M83.64M45.13M20.84M
EBITDA-52.98M-44.30M-44.40M-122.02M-89.41M-79.97M
Net Income-50.95M-50.99M-49.66M-130.49M-99.39M-93.92M
Balance Sheet
Total Assets358.25M397.87M307.42M356.39M339.50M343.99M
Cash, Cash Equivalents and Short-Term Investments138.06M191.35M100.86M165.94M124.65M151.37M
Total Debt698.00K1.37M1.97M3.15M13.60M14.13M
Total Liabilities75.36M87.84M93.36M105.26M91.39M81.26M
Stockholders Equity282.89M310.03M214.06M251.13M248.11M262.72M
Cash Flow
Free Cash Flow-61.55M-71.43M-63.04M-94.03M-89.36M-89.84M
Operating Cash Flow-48.82M-64.03M-62.38M-93.91M-89.23M-89.78M
Investing Cash Flow-24.29M-7.40M-657.00K-124.00K-129.00K-51.85M
Financing Cash Flow-163.00K163.18M-2.46M135.40M61.84M243.43M

OssDsign AB Technical Analysis

Technical Analysis SentimentNegative
Last Price3.33

Price Trends

50DMA3.51Negative
100DMA3.77Negative
200DMA4.41Negative

Market Momentum

MACD0.01Positive
RSI41.73Neutral
STOCH23.64Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:OSSD, the sentiment is Negative. The current price of 3.33 is below the 20-day moving average (MA) of 3.50, below the 50-day MA of 3.51, and below the 200-day MA of 4.41, indicating a bearish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 41.73 is Neutral, neither overbought nor oversold. The STOCH value of 23.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:OSSD.

OssDsign AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

SE:OSSD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:XVIVOSE:XVIVO64NeutralSEK 6.17B47.925.89%―17.83%330.94%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
SE:BACTI.BSE:BACTI.B53NeutralSEK 544.93M86.391.93%―-0.51%―
SE:SEDANASE:SEDANA49NeutralSEK 921.85M-26.71-3.88%―0.42%15.03%
SE:OSSDSE:OSSD46NeutralSEK 368.38M-7.36――-11.89%-11.85%
SE:INTEG.BSE:INTEG.B45NeutralSEK 242.60M-5.75-20.71%―1.43%4.98%
SE:HEARTSE:HEART44NeutralSEK 134.27M-2.23-54.68%―――

* General Sector Average

Performance Comparison

-50%0%50%SE:OSSDSE:XVIVOSE:BACTI.BSE:INTEG.BSE:HEARTSE:SEDANADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:OSSD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:OSSDOssDsign AB3.33-7.41-68.99%
SE:XVIVOXvivo Perfusion AB196.0031.0018.79%
SE:BACTI.BBactiguard Holding AB15.55-3.20-17.07%
SE:INTEG.BIntegrum AB Class B8.27-0.44-5.05%
SE:HEARTScandinavian Real Heart AB15.801.5010.50%
SE:SEDANASedana Medical AB9.28-0.33-3.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026